Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:08 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 316 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: additional biopsies Clear all

Conditions: Lymphoplasmacytic Lymphoma, Waldenstrom Macroglobulinemia
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Ibrutinib, Positron Emission Tomography, Rituximab, Venetoclax, Zanubrutinib; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 150
States / cities: Tucson, Arizona • Irvine, California • Coral Gables, Florida + 113 more

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 25 Years and older · Female only
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Diabetic Nephropathies, Kidney Diseases, Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2
Interventions: Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Renin-angiotensin-aldosterone system blockade, Glucagon-like peptide-1 receptor agonists (GLP 1 RA), Mineralocorticoid Receptor Antagonists(MRAs); Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Squamous Cell Carcinoma of the Head and Neck
Interventions: Panitumumab, Surgery, Radiation Therapy; Drug · Procedure
Lead sponsor: Neal Ready; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Durham, North Carolina

Conditions: Parkinson Disease
Interventions: Colonoscopy; Procedure
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 45 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Lymphoma, Hodgkin Disease
Interventions: tumor tissue aspiration, phlebotomy; Procedure
Lead sponsor: Stanford University; Other
Eligibility: Up to 21 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2015
U.S. locations: 1
States / cities: Stanford, California

Conditions: Melanoma
Interventions: autologous tumor cells plus GM-CSF-in Adjuvant; Biological
Lead sponsor: Craig L Slingluff, Jr; Other
Eligibility: 18 Years to 85 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Cancer, Immunotherapy, Advanced Solid Tumors Cancer, Bladder Cancer, TNBC, Triple Negative Breast Cancer, Colorectal Cancer, DMMR Colorectal Cancer, MSI-H Colorectal Cancer, Endometrial Cancer, Head and Neck Cancer, Kidney Cancer, Liver Cancer, NSCLC (Non-small-cell Lung Cancer), Skin Cancer, Melanoma (Skin Cancer)
Interventions: Biopsy; Procedure
Lead sponsor: Elephas; Industry
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2038
U.S. locations: 8
States / cities: Fort Smith, Arkansas • Frederick, Maryland • Springfield, Missouri + 4 more

Conditions: Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Lymphoma, B-Cell Lymphoma
Interventions: Obinutuzumab, Venetoclax, Magrolimab, Acetaminophen, Diphenhydramine, Prednisone/prednisolone, Methylprednisolone, CT Scan chest/abdomen/pelvis, MRI, 18-FDG-PET, Bone Marrow Biopsy, Bone Marrow Aspiration; Drug · Diagnostic Test · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Abnormalities
Interventions: Contrast Enhanced Spectral Mammography (CESM); Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 25 Years and older · Female only
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Non-Small Cell Lung Cancer
Interventions: CDX-1401, MPDL3280A; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: cisplatin, everolimus, gene expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, biopsy; Drug · Genetic · Other + 1 more
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Liver Transplantation
Interventions: Anti-Thymocyte Globulin - Rabbit, darTreg Infusion, Everolimus, Tacrolimus, Mycophenolate mofetil, Prednisone, Acetaminophen, Diphenhydramine, Anti-Infective Prophylaxis, Leukapheresis, Blood draws, Liver biopsies, Liver transplantation; Biological · Drug · Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 21 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 3
States / cities: San Francisco, California • Chicago, Illinois • Rochester, Minnesota

Conditions: Breast Cancer, Stage 0
Interventions: Breast MRI, Laboratory Biomarker Analysis; Diagnostic Test · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 122 participants
Timeline: 2018 – 2032
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Ovarian Cancer
Interventions: Blood-Based Ovarian Cancer Screening Test; Diagnostic Test
Lead sponsor: Mercy BioAnalytics, Inc.; Industry
Eligibility: 50 Years and older · Female only
Enrollment: 1,750 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Waltham, Massachusetts • Austin, Texas

Conditions: Barretts Esophagus With Dysplasia, Intramucosal Adenocarcinoma
Interventions: Study Driven Procurement of Biopsies; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Leukemia
Interventions: 5-azacitidine, Allogeneic Hematopoietic Cell Transplantation (HCT); Drug · Procedure
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years to 68 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Inflammatory Bowel Diseases
Interventions: Serial Biopsy; Procedure
Lead sponsor: Terrence A Barrett; Other
Eligibility: 18 Years to 90 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma, Gastric Mucosa-Associated Lymphoid Tissue Lymphoma, Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma, Lymphoma, Extranodal Marginal Zone Lymphoma
Interventions: Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging, Nemtabrutinib, Positron Emission Tomography, Rituximab; Procedure · Drug · Biological
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Duarte, California

Conditions: Colorectal Cancer
Interventions: Atezolizumab, Bevacizumab, Cobimetinib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 4
States / cities: Aurora, Colorado • New York, New York • Nashville, Tennessee + 1 more

Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related, Myelodysplastic Syndrome
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Busulfan, Chest Radiography, Computed Tomography, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Decitabine and Cedazuridine, Echocardiography Test, Emavusertib, Enasidenib, Epoetin Alfa, Fludarabine, Gemtuzumab Ozogamicin, Gilteritinib, Liposome-encapsulated Daunorubicin-Cytarabine, Luspatercept, Melphalan, Multigated Acquisition Scan, Mutation Carrier Screening, Olutasidenib, Placebo Administration, Positron Emission Tomography, Quizartinib, Total-Body Irradiation, Venetoclax; Procedure · Drug · Other + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 347
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 265 more

Conditions: Solitary Pulmonary Nodules
Interventions: near infrared fluorescence imaging (NIFI), Indocyanine Green; Device · Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Non-ischemic Cardiomyopathy
Interventions: additional biopsies; Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: Not listed
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 2
States / cities: Rochester, Minnesota • Philadelphia, Pennsylvania

Conditions: Pancreatic Cancer
Interventions: TTI-101, Stereotactic body radiation therapy; Drug · Radiation
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 2
States / cities: Aurora, Colorado • St Louis, Missouri

Search by objective public record fields.

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

Use of Molecular Breast Imaging (MBI) to Detect Additional Disease in Women With Breast Cancer Who Are About to go to Surgery

Transformative Research in Diabetic Nephropathy 2.0

Identification of Gene Expression Signature for Panitumumab Sensitivity in Untreated Locally Advanced SCCHN

Parkinson's Disease Biomarkers in Nerve Cells in the Gut

Consent for Obtaining Additional Tissue at the Time of a Diagnostic Biopsy

Pilot Study for the Evaluation of the Efficacy of Vaccination With Autologous Tumor Cells Plus Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) - in - Adjuvant, Followed by Systemic Low-dose-interleukin-2 (IL-2) Administration, in Patients With High Risk Melanoma

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

Use of Contrast Enhanced Spectral Mammography (CESM) for Women With Palpable Breast Abnormalities

Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer

Cisplatin and Everolimus in Treating Patients With Advanced Solid Tumors

Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation

MRI Characterization of Mammographically Detected DCIS

Safety in Ovarian Cancer for Average-Risk Women - Analysis

Utility Of Mutational Load As A Predictor For Endoscopic Treatment Response In Barrett's Esophagus

Pre-Transplant 5-Azacitidine In Patients With High-Risk Myelodysplastic Syndrome Who Are Candidates For Allogeneic Hematopoietic Cell Transplant

Regulation of Mucosal Healing in Inflammatory Bowel Disease

Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma

Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Near Infrared Fluorescence Imaging With Indocyanine Green

Electrogram-Guided Myocardial Advanced Phenotyping

Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma